ReviewJournal of inflammation research2026
Microbiota-Associated Metabolites as Immunometabolic Regulators of Glomerular Inflammation: Disease-Specific Mechanisms and Therapeutic Opportunities.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoglobulin A nephropathy (IgAN), membranous nephropathy (MN), and lupus nephritis (LN) are immune-mediated glomerular diseases in which dysregulated adaptive immunity converges with innate inflammatory and filtration-barrier injury. Clinical relapse and incomplete recovery despite upstream immune control motivate investigation of additional injury modifiers. Main Body: This review evaluates five microbiota-associated metabolite families-short-chain fatty acids (SCFAs), tryptophan-derived metabolites, aromatic amino acid-derived uremic solutes, trimethylamine N-oxide (TMAO), and bile acids-across three modules: immune-tolerance failure, innate inflammatory amplification, and filtration-barrier disruption. In IgAN, multi-omics data showing preserved or elevated systemic acetate with reduced glomerular free fatty acid receptor 2/3 (FFAR2/FFAR3)-associated signaling suggest impaired renal SCFA sensing, but do not establish receptor competence as the dominant target. In MN, disease-specific studies support podocyte injury mediated by complement C3a and its receptor (C3a/C3aR) and complement-associated NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3)-caspase-1-gasdermin D (GSDMD) pyroptosis as related injury processes, whereas proposed SCFA-regulatory T cell (Treg)-B-cell and SCFA-inflammasome interactions remain largely hypothesis-generating; experimental Lactobacillus-indole-aryl hydrocarbon receptor (AhR) data provide preliminary evidence. In LN, microbiota-dependent tryptophan pathway perturbation and treatment-associated metabolomic changes support the kynurenine-to-tryptophan ratio as a readily measurable candidate biomarker requiring prospective validation. Across diseases, interpretation requires separating microbial production from renal retention, metabolite abundance from receptor signaling competence, and total from unbound exposure for protein-bound solutes. Conclusion: Microbiota-associated metabolites constitute a plausible immunometabolic layer rather than established causal pathways in immune-mediated glomerular disease. Priorities include disease-specific longitudinal phenotyping, compartment-resolved metabolite measurement, target-engagement studies, and biomarker-embedded clinical trials before therapeutic claims are advanced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.